The Vault Complex Is Significantly Involved in Therapeutic Responsiveness of Endocrine Tumors and Linked to Autophagy under Chemotherapeutic Conditions.
BON
EDPM
MVP
NCI-H295
TEP-1
TNF alpha
VPARP
adrenocortical carcinoma
autophagy
endocrine tumor
neuroendocrine tumor
vault RNA
vault complex
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Mar 2023
15 Mar 2023
Historique:
received:
20
02
2023
revised:
10
03
2023
accepted:
13
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Cancers display dynamic interactions with their complex microenvironments that influence tumor growth, invasiveness, and immune evasion, thereby also influencing potential resistance to therapeutic treatments. The tumor microenvironment (TME) includes cells of the immune system, the extracellular matrix, blood vessels, and other cell types, such as fibroblasts or adipocytes. Various cell types forming this TME secrete exosomes, and molecules thereby released into the TME have been shown to be important mediators of cellular communication and interplay. Specific stressors in the TME, such as hypoxia, starvation, inflammation, and damage, can furthermore induce autophagy, a fundamental cellular process that degrades and recycles molecules and subcellular components, and recently it has been demonstrated that the small non-coding vault RNA1-1 plays a role as a regulator of autophagy and the coordinated lysosomal expression and regulation (CLEAR) network. Here, we demonstrate for the first time that intra-tumoral damage following effective therapeutic treatment is linked to specific intracellular synthesis and subsequent exosomal release of vault RNAs in endocrine tumors in vitro and in vivo. While we observed a subsequent upregulation of autophagic markers under classical chemotherapeutic conditions, a downregulation of autophagy could be detected under conditions strongly involving inflammatory cascades.
Identifiants
pubmed: 36980669
pii: cancers15061783
doi: 10.3390/cancers15061783
pmc: PMC10046419
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : HA 8297/1-1 and project no. 314061271, TRR 205/1
Organisme : the project was supported by Immuno-TargET under the umbrella of University Medicine Zurich to C.H., F.B. and S.N.
ID : no grant number available
Références
Nat Rev Mol Cell Biol. 2020 Feb;21(2):101-118
pubmed: 31768005
J Cell Biol. 1991 Jan;112(2):225-35
pubmed: 1988458
Int J Mol Sci. 2021 Dec 12;22(24):
pubmed: 34948156
Mol Cell Endocrinol. 2016 Mar 5;423:87-95
pubmed: 26768118
J Cell Biol. 1986 Sep;103(3):699-709
pubmed: 2943744
Cancer Cell Int. 2019 Jul 29;19:199
pubmed: 31384174
Nat Commun. 2017 Feb 17;8:14448
pubmed: 28211508
Sci Adv. 2022 Feb 11;8(6):eabj7795
pubmed: 35138889
Nat Commun. 2015 May 08;6:7030
pubmed: 25952297
Mol Cancer. 2019 Jan 24;18(1):17
pubmed: 30678689
Endocr Relat Cancer. 2014 Apr 28;21(3):383-94
pubmed: 24532475
Cells. 2022 Sep 26;11(19):
pubmed: 36230955
EMBO J. 2017 Jul 3;36(13):1811-1836
pubmed: 28596378
Mol Aspects Med. 2006 Oct-Dec;27(5-6):495-502
pubmed: 16973206
Autophagy. 2022 Jan;18(1):191-203
pubmed: 33960270
Cancers (Basel). 2022 Jun 03;14(11):
pubmed: 35681764
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2188-9
pubmed: 22308477
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Open Biol. 2020 Feb;10(2):190307
pubmed: 32070232
Endocr Relat Cancer. 2016 Oct;23(10):825-37
pubmed: 27550961
J Biol Chem. 2007 Aug 17;282(33):24131-45
pubmed: 17580304
EMBO J. 2009 Nov 4;28(21):3450-7
pubmed: 19779459
Autophagy. 2019 Aug;15(8):1463-1464
pubmed: 31006338
Cell. 2019 Feb 21;176(5):1054-1067.e12
pubmed: 30773316
EMBO J. 2003 Jun 16;22(12):3027-38
pubmed: 12805217
Front Immunol. 2017 Sep 04;8:1075
pubmed: 28928743
Front Immunol. 2018 Oct 17;9:2334
pubmed: 30386331
Cancers (Basel). 2020 Nov 20;12(11):
pubmed: 33233671
Nucleic Acids Res. 2015 Dec 2;43(21):10321-37
pubmed: 26490959